Vision Zero in oncology - 02/09/2019 Call for a comprehensive master plan for preventing and treating cancer While a cancer-free world may seem unrealistic given the increasing numbers of cancer cases, we need to reach a social consensus that cancer deaths are unacceptable and that everything possible must be done to prevent them. Leading cancer researchers around the world are calling for more investment in prevention research and cancer screening to move towards the vision of a near cancer-free world.https://www.gesundheitsindustrie-bw.de/en/article/news/call-for-comprehensive-master-plan-preventing-treating-cancer
Press release - 27/06/2019 Velabs Therapeutics Announces €3 Million Series B Financing to Advance its Functional Antibody Screening Programme Velabs Therapeutics GmbH, a leader in rapid screening of functional therapeutic antibodies, today announced the closing of a €3 million Series B financing round to advance its functional antibody screening programme and to strengthen its own pipeline of preclinical functional antibodies against diseases with poor treatment options. Further details of the financing round were not disclosed.https://www.gesundheitsindustrie-bw.de/en/article/press-release/velabs-therapeutics-announces-eur3-million-series-b-financing-advance-its-functional-antibody-screening-programme
New edition - 24/05/2019 Tumour metastasis Cancer is usually not curable when metastases have formed in the body. Metastases are often resistant to drugs that have successfully eliminated the primary tumour. The basic features of the complex process of metastasis are now known, but many details still remain elusive. Intensive research activities are focusing on new therapeutic concepts aimed at developing effective anti-metastatic therapies.https://www.gesundheitsindustrie-bw.de/en/article/dossier/tumour-metastasis
Expert interview - 13/05/2019 Innovation management in the life sciences – Inova DE provides insights Personalized medicine, medical technology, digital health and artificial intelligence are revolutionizing diagnostics and product development. Analyses are becoming faster and more precise, and data volumes can now be networked and used effectively. The goal of improving people's quality of life is within reach, and this will also strengthen Germany’s future viability. However, not every good idea can be turned into a marketable commodity.…https://www.gesundheitsindustrie-bw.de/en/article/news/innovation-management-in-the-life-sciences-inova-de-provides-insights
Article - 23/04/2019 How can care infrastructures benefit from digitization? The pilot project NeCTra (Networking - Care - Transparency) investigates how care processes within an urban social environment can be improved by using digital technologies. The goal is to bring together all partners and institutions in real time so that people in need of care and those seeking advice receive appropriate support more quickly.https://www.gesundheitsindustrie-bw.de/en/article/news/how-can-care-infrastructures-benefit-from-digitization
Article - 18/03/2019 EHR and PHR: digital records in the German healthcare system EHRs, i.e. electronic health records (German: Patientenakte, ePA), are hailed as the key to increasing the quality of care. The Appointment Service and Supply Act (TSVG), adopted on 14th March 2019, requires the German statutory health insurance funds to provide policyholders with electronic health records from 1st January 2021 onwards.https://www.gesundheitsindustrie-bw.de/en/article/news/ehr-and-phr-digital-records-in-the-german-healthcare-system
Article - 24/01/2019 Scientists to combat antibiotic-resistant bacteria in wastewater In Germany, around 1,500 tonnes of antibiotics per year are administered to humans and animals. As a result, more and more bacteria are developing resistance to common antibiotics. As part of HyReKA, a cooperative project funded by the BMBF, scientists led by Professor Thomas Schwartz from the KIT are investigating how antibiotic-resistant pathogens spread and how they can be prevented from doing so.https://www.gesundheitsindustrie-bw.de/en/article/news/scientists-to-combat-antibiotic-resistant-bacteria-in-wastewater
Expert interview - 16/01/2019 Cybersecurity is an important issue for the pharmaceutical industry In an increasingly interconnected world, the pharmaceutical and biotechnology sectors need to be aware of cybersecurity threats in manufacturing. We talked about these threats with Holger Mettler who is in charge of computer system validation and cybersecurity at Exyte (formerly M + W), a global enterprise that designs, engineers and constructs complex manufacturing facilities and buildings for the life sciences industry.https://www.gesundheitsindustrie-bw.de/en/article/news/cybersecurity-is-an-important-issue-for-the-pharmaceutical-industry
Company profile - 19/12/2018 With DiHeSys into integrated digital healthcare The founders and partners of DiHeSys have big ambitions: "We have to build a complete ecosystem around the patient," says Dr. Markus Dachtler, managing director of DiHeSys. The company develops products and services for an industry in transition, provides answers to trends such as personalized medicine, 2D- and 3D-printing technologies and platform technologies. The company’s motto: no isolated solutions, but a comprehensive range of…https://www.gesundheitsindustrie-bw.de/en/article/news/with-dihesys-into-integrated-digital-healthcare
Anniversary - 12/12/2018 15 years of BIOPRO: Pooling competencies – pushing innovations This is the leitmotif of BIOPRO Baden-Württemberg GmbH, which was founded in 2003. 15 years is a good time to pause for a moment and take a look at BIOPRO’s work and achievements. As a central point of contact and wholly-owned subsidiary of the Baden-Württemberg government whose main objective is to promote networking, BIOPRO knows only too well that progress is not made alone, but in collaboration with others.https://www.gesundheitsindustrie-bw.de/en/article/press-release/15-years-of-biopro-pooling-competencies-pushing-innovations
Press release - 10/12/2018 High distinction for stem cell researcher Andreas Trumpp This year's State Research Prize of Baden-Württemberg awarded for outstanding achievements in applied research goes to Andreas Trumpp from the German Cancer Research Center (DKFZ) and the Heidelberg Institute for Stem Cell Technology and Experimental Medicine (HI-STEM). Theresia Bauer, State Minister of Science, Research and the Arts, presented the award, which carries a monetary prize of €100.000, at a festive ceremony on December 10, 2018.https://www.gesundheitsindustrie-bw.de/en/article/press-release/high-distinction-for-stem-cell-researcher-andreas-trumpp
Article - 30/10/2018 Eucor – bringing the European Campus to life Enrolling at one university and being able to use the services of a total of five universities is unique in the European Research Area. A model project called Eucor - The European Campus offers students and young scientists this opportunity at universities in the Germany-France-Switzerland border triangle, which simultaneously acts as a borderless academic area for the sciences. https://www.gesundheitsindustrie-bw.de/en/article/news/eucor-bringing-the-european-campus-to-life
Industry report 2018 - 27/09/2018 The healthcare industry – the innovation driver of the 21st century: opportunities and challenges BIOPRO Baden-Württemberg’s new industry report entitled "The Healthcare Industry 2018: Facts and Figures for Baden-Württemberg" has just been published in both German and English. The topic neatly dovetails with the state’s political activities. An evaluation of the region carried out on behalf of the Baden-Württemberg government has clearly recognised the importance of the healthcare sector as a driver of innovation.https://www.gesundheitsindustrie-bw.de/en/article/press-release/the-healthcare-industry-the-innovation-driver-of-the-21st-century
Dossier - 28/08/2018 With molecular diagnostics to biomarker-based personalised therapy Diagnosing suitable biomarkers is a prerequisite for tailoring personalised therapies to patient heterogeneity. Genetic tests and genome sequencing play a key role in these diagnoses. Up until now, personalised therapy has achieved the greatest success in the field of oncology. However, personalised treatments are also gaining in importance for treating other diseases.https://www.gesundheitsindustrie-bw.de/en/article/dossier/with-molecular-diagnostics-to-biomarker-based-personalised-therapy
Company profile - 31/07/2018 Acousia Therapeutics: medicines for deafness Deafness is one of the most common sensory disorders in the world: in Germany alone, around eleven million people suffer from hearing loss. So far there is no real therapy, the symptoms can only be alleviated to a greater or lesser degree. This is what researchers from the Tübingen-based company Acousia Therapeutics want to change: they have identified drug candidates that can protect sensory hair cells and support their function.https://www.gesundheitsindustrie-bw.de/en/article/news/acousia-therapeutics-medicines-for-deafness
Company profile - 26/07/2018 evid - therapy recommendations at a glance There are over 700 treatment guidelines in Germany alone, and each is up to several hundred pages long. Can doctors still stay on top of things? A start-up company from Mannheim called evid is developing a software that can retrieve relevant therapy recommendations for individual patients from the huge pile of paperwork. In March 2018, the founding trio won first place of the eHealthForum Freiburg start-up competition.https://www.gesundheitsindustrie-bw.de/en/article/news/evid-therapy-recommendations-at-a-glance
Article - 03/07/2018 The digital laboratory is picking up speed A new team at the Fraunhofer IPA is developing digital laboratory systems to support industrial partners in planning and managing laboratory processes. This benefits companies in terms of quality assurance, economic efficiency and, notably, ergonomic improvements to the work place.https://www.gesundheitsindustrie-bw.de/en/article/news/the-digital-laboratory-is-picking-up-speed
Expert interview - 26/06/2018 Genome analyses: "Germany lags behind dramatically" Around 6,000 genetic diseases can be diagnosed using genetic tests. Genetic testing enables the accurate identification of diseases especially when symptoms are unclear, and also allows statements to be made about disease progression. However, restrictive regulations considerably hinder the use of genetic diagnostics. BIOPRO spoke with Dr. Dr. Saskia Biskup, a human genetics specialist and co-founder of the Tübingen-based company CeGaT. https://www.gesundheitsindustrie-bw.de/en/article/news/genome-analyses-germany-lags-behind-dramatically
Article - 13/06/2018 TeleDerm: Rapid help from a dermatologist via teleconsultation Some geographical locations have relatively few specialist medical practices. Getting an appointment with a specialist if you live in such areas might mean a long wait or a long journey. A study being carried out at the University of Tübingen is looking to improve this situation: the TeleDerm project involves dermatologists using telemedicine to assess skin disorders from images taken by GPs.https://www.gesundheitsindustrie-bw.de/en/article/news/telederm-rapid-help-from-a-dermatologist-via-teleconsultation
Article - 06/06/2018 Robots for assisting with care and treatment in nursing homes and hospitals Robotic systems have great potential in the healthcare sector. For example, intelligent care aids, such as robotic technologies, extended care trolleys and lifters make life easier for nursing home and hospital staff. Mobile robots that assist with transport tasks or guiding people can help patients become more independent.https://www.gesundheitsindustrie-bw.de/en/article/news/robots-for-assisting-with-care-and-treatment-in-nursing-homes-and-hospitals
Article - 16/05/2018 Telemedical neurology council helps speed up stroke treatment Stroke units save lives because specialist treatment is absolutely crucial for stroke patients. However, not all clinics have neurological specialists available 24/7, so telemedicine provides a good solution to the problem. Studies show that telemedical consultations can considerably improve the treatment of stroke patients.https://www.gesundheitsindustrie-bw.de/en/article/news/telemedical-neurology-council-helps-speed-up-stroke-treatment
Article - 28/03/2018 New method for analysing epigenetic modifications - in the service of medical progress It is not just genetic factors that influence developmental processes and diseases; it is becoming increasingly evident that epigenetic changes play a major role too. Thanks to a new method developed at the University of Stuttgart, epigenetic processes can now be investigated in living cells.https://www.gesundheitsindustrie-bw.de/en/article/news/new-method-for-analysing-epigenetic-modifications-in-the-service-of-medical-progress
Article - 21/02/2018 HepaRegeniX – a start-up is taking it up a step! HepaRegeniX, a biotech company founded in 2016, specialises in developing drugs that restore the regenerative capacity of diseased livers. The three founders of the biotech start-up, Prof. Dr. Lars Zender, Prof. Dr. Stefan Laufer and Dr. Wolfgang Albrecht, anticipate starting clinical testing of the first drug candidate in 2019.https://www.gesundheitsindustrie-bw.de/en/article/news/heparegenix-a-start-up-is-taking-it-up-a-step
Press release - 21/02/2018 German Cancer Award for Michael Baumann Michael Baumann, Chairman and Scientific Director of the German Cancer Research Center (DKFZ) in Heidelberg, receives the 2017 German Cancer Award in the category "Translational Research". The science award, which is sponsored by the German Cancer Society and the German Cancer Foundation, is one of the most prestigious distinctions in cancer medicine in Germany.https://www.gesundheitsindustrie-bw.de/en/article/press-release/german-cancer-award-for-michael-baumann
Article - 15/01/2018 Blockchain technology as an opportunity for more transparency and self-determination In the healthcare sector, blockchain technology is still in the early stages of development, although it has huge potential in this field. It is expected that patients will particularly benefit from the introduction of a decentralised database for managing and sharing health-related information with treating physicians. Statutory health insurance companies become less important as intermediaries. But how exactly does this technology work? https://www.gesundheitsindustrie-bw.de/en/article/news/blockchain-technology-as-an-opportunity-for-more-transparency-and-self-determination